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Tumor infiltrating neutrophils have been implicated in malignant development and 
progression but mechanisms are ill-defined. Neutrophils produce a proliferation-inducing ligand 
APRIL/TNFSF13, a factor that promotes development of tumors from diverse origins, including 
diffuse large B-cell lymphoma (DLBCL). High APRIL expression in DLBCL correlates with 
reduced patient survival, but the pathway(s) dictating APRIL expression are not known. Here we 
show that all blood neutrophils constitutively secrete APRIL, and inflammation-associated 
stimuli such as TNF further upregulate APRIL. In a significant fraction of DLBCL patients tumor 
cells constitutively produced the ELC-CXC chemokine CXCL-8 (IL-8), enabling them to recruit 
APRIL-producing blood neutrophils. CXCL-8 production in DLBCL was unrelated to the cell of 
origin, as APRIL-producing neutrophils infiltrated CXCL-8+ DLBCL from both germinal center 
(GC) and non-GC subtypes. Rather, CXCL-8 production implied events affecting DNA 
methylation and acetylation. Overall, our results showed that chemokine-mediated recruitment of 
neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression.  
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Introduction 
The microenvironment is a key player in tumor development (1). Tumor 
microenvironment comprises stromal cells and endothelial cells. When tumor development is 
associated to a host inflammatory reaction, infiltrating leukocytes from the blood become also 
part of the microenvironment.  Myeloid cells often infiltrate tumors, and their pro or anti-tumoral 
role, especially with macrophages, has been extensively studied (2, 3). 
In addition to the well-described role for macrophages, a role for neutrophils in the 
development of tumors has been recently proposed (4). Neutrophils have been reported to 
increase cancer genetic instability by their production of nitric oxide derivatives and reactive 
oxygen species (5), to promote angiogenesis by their secretion of pro-angiogenic factors (6, 7), 
and also to produce immunosuppressive factors, such as IL-10 (8). For all these reasons, 
neutrophil infiltration of several solid tumors has been associated with a poorer outcome for 
patients (9). On the other hand, neutrophils may also act as anti-tumoral immune cells via their 
expression of the apoptotic ligand TRAIL (10). Furthermore, elastase, a protease commonly 
secreted by neutrophils, is also an anti-angiogenic factor (11). Hence, the role of neutrophils in 
tumor development is contrasted, and it is believed that neutrophils may be polarized, in effector 
cells with either pro- or anti-tumoral function, very similarly to macrophages (12).  
Neutrophils produce a proliferation inducing ligand (APRIL, TNFSF13) (13). The initial 
reported function of APRIL was induction of increased proliferation in tumor cells (14). This role 
has been further substantiated in colorectal cancers (15). Hematologic tumors from the B-cell 
lineage also depend on APRIL (16). The best-documented B-cell malignancy depending on 
APRIL is chronic lymphocytic leukemia (CLL). In CLL, APRIL is of stromal origin, and 
prolongs the in vitro survival of primary CLL samples (17, 18). Furthermore, APRIL 
overexpression in mice leads to CLL-like neoplasm development. In patients, high APRIL serum 
level correlates with reduced patient survival (19-22). Regarding DLBCL, APRIL also acts as an 
in vitro survival factor (23), and a high level of APRIL in tumor lesions is a risk factor, at least in 
patients treated with CHOP chemotherapy (24). While DLBCL tumor cells may aberrantly 
produced APRIL upon translocations involving the APRIL gene and the immunoglobulin heavy 
chain locus (25), we previously observed that most of APRIL originates from infiltrating 
neutrophils (24). Here, we are describing the pathway conducting to high APRIL expression in 
DLBCL lesions. 
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Methods 
Human and animal experimentations 
The Basel and Grenoble ethical committees approved human experimentations. The basel 
DLBCL cohort has been previously described (26). Frozen DLBCL biopsies and corresponding 
formalin-fixed paraffin-embedded DLBCL biopsies used for mRNA analysis were obtained after 
patients’ informed consent from the centre of biological resources (Grenoble, France). Two 
pathologists independently reviewed DLBCL diagnosis. In some cases, GC and non-GC DLBCL 
subtypes were defined by immunohistochemistry with the combination of CD10, bcl-6 and Mum-
1/IRF-4 markers as reported (27). Peripheral blood leukocytes were obtained from healthy donors 
(French blood institute, Grenoble). The Geneva CELEA ethical committee approved mouse 
experimentations. Four weeks-old immunodeficient NOG mice (Taconic) were engrafted with 
cord blood-derived CD34+ hematopoietic stem and progenitor cells (French blood institute) two 
days after chemical myeloablative treatment. Engraftment consisted in intravenous injection of 
105 CD34+ cells. Fourteen weeks after cell injection, engraftment level was monitored with the 
analysis of human CD45+ cells among total blood leukocytes by flow cytometry (Attune, Life 
technologies). 107 tumor cells were injected subcutaneously in mice harboring at least 10% of 
engraftment level.  
 
Neutrophil stimulation 
Neutrophils were purified following standard dextran sedimentation followed by Ficoll-
paque centrifugation and FACS-sorting based on FSChigh SSChigh morphology on a FACS-Aria 
(BD Biosciences). After purification CD13+CD16+ neutrophils represented more than 85% and 
80%, respectively. Viability assessed by trypan blue staining was > 95% after 24 h. Conditioned 
supernatants were obtained by incubating neutrophils at 106 cells per ml in RPMI 1640 
supplemented with 10% heat-inactivated FCS. Cell stimulation was performed with either fMLP 
(6.10-9M, Sigma) or phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma) or TNF (100 
ng/ml, Adipogen). Cell-free supernatant was analysed for secreted APRIL by ELISA using 
manufacturer’s instructions (eBioscience). Cells were also harvested for APRIL mRNA 
expression at 6 and 12 h. 
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For the analysis of H2O2 production, 0.5 x 106 cells were mixed in a 96-well plate with 20 
mM glucose, 20 µM luminol and 10U/ml HRP and with the activators described above. 
Luminescence was recorded at 37°C every 15 s for 10 min using a Victor3 1420 multilabel 
counter (Perkin Elmer). 
 
Immunohistochemistry 
Biopsies were stained for APRIL-producing cells (Stalk-1 staining), elastase, and CD20 
as previously described (24). Rabbit anti-CXCL-8 (Life technologies) was used at 5 µg/ml after 
heat-induced antigen retrieval in 10 mM Tris, 1 mM EDTA pH 9.0. Microscopy images were 
visualized with a BX-41 microscope (Olympus) with a plan 40x/0,65 air objective and a plan 
100x/1,25 oil objective. Images were captured with a DP70 color camera and treated with the 
AnalySIS software. Confocal analysis was performed on an LSM 510 microscope (Carl Zeiss) 
with a plan 40x/1.30 oil-immersion objective. 
 
Flow cytometry 
All fluorochrome-conjugated antibodies were from BD biosciences. APRIL staining with 
Stalk-1 (detecting APRIL-producing cells) was performed after cell permeabilization as 
previously described (24). Fluorescence was analysed by flow cytometry on a FACS CALIBUR 
or an Accuri C6 (BD biosciences). CD20+ and CD20- fraction of frozen primary DLBCL were 
purified by FACS-sorting on a FACS-Aria (BD biosciences). CD19+ B-cell subsets were purified 
from tonsils according to naive (IgD+/CD38-), GC (CD38+) and memory (IgD-/CD38-) 
phenotype. Dead cells were excluded by 7-AAD staining. Purity and viability was > 95%. 
 
PCR  
For the detection of ELC-CXC chemokine mRNA, 30 sections of 20 µm from frozen 
DLBCL biopsies were pooled, and total RNA was extracted with the RNeasy micro kit (Qiagen). 
cDNA was generated using random primers and the SuperScript II reverse transcriptase 
(Invitrogen). For CXCL-2 5’-ctttccagccccaaccat-3’ and 5’-ggatttgccatttttcagca-3’, for CXCL-3 
5’-cccaaaccgaagtcatagcc-3’ and 5’-agttccccaccctgtcattt-3’, for CXCL-5 5’-ccaatcttcgctcctccaat-3’ 
and 5’-tccttgtttccaccgtcca-3’, for CXCL-6 5’-accccttctttccacactgc-3’ and 5’-
ggaggctaccacttccacct-3’, for CXCL-8 5’-cggaaggaaccatctcactg-3’ and 5’-agcactccttggcaaaactg-
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3’, for CCL-7 5’-cagaaggaccaccagtagcc-3’ and 5’-gcatcccacagtttttacagc-3’, for CCL-13 5’-
cagaggagcagagaggcaaa-3’ and 5’-gccagaggagaatggaaaagtc-3’, for CCL-14 5’-
gctctcctcccacaacagc-3’ and 5’-gccaatgagtaaatcccgtaga-3’ were used as forward and reverse 
primers, respectively. Denaturation was performed at 94°C, annealing at 55°C and extension at 
72°C, 1 mn each. Forty cycles were applied. Amplified PCR products were visualized on agarose 
gels and ethidium bromide staining. To exclude genomic DNA amplification, primers spanning 
intronic sequences were used.  
For quantitative analysis, total RNA was extracted using Trizol (Invitrogen), and cDNA 
generated as above. Quantification was performed using the iCycler iQ Real-Time PCR 
Detection system (Bio-Rad) and a SYBRgreen-based kit (iQ SupermixBio-Rad). The intron 
spanning forward 5'- atgggtcaggtggtgtctcg-3' and reverse 5'- tccccttggtgtaaatggaaga-3' primers 
were used for the detection of human APRIL. Expression levels were normalized using 18S 
rRNA. Results were quantified using a standard curve generated with serial dilutions of input 
DNA.  
 
Chemokine profiling and ELISA 
30 sections of 20 µm from frozen DLBCL biopsies were pooled, lyzed in Na phosphate 
0.01 M, EDTA 1 mM, EGTA 1mM, NaF 1 mM, NaCl 0.15 M pH=7.2, containing 1 % Triton X-
100, 0.1% NaDOC, 1 mM PMSF and complete mini cocktail protease inhibitors from Roche.  
Protein quantification in lysates was performed with a BCA protein assay kit (Pierce). The 
human cytokine profiling kit, and CXCL-8 ELISA were from R&D. DLBCL OCI cell lines were 
provided by M. Minden (Ontario Cancer Institute, Toronto, Canada). Dr A. Wiestner (NIH, 
Bethesda, MD) provided the Su-DHL cell lines. B593, HT, HBL-1, K422, Nu-DUL-1, Pfeiffer, 
RC-K8, RIVA, and U2932 have been already described (28, 29). 0.5 x 106 DLBCL cells per ml 
were incubated for 48h for supernatant conditioning. Cell stimulation was performed with an 
anti-BCR (goat anti-human Ig, 1 µg/ml, Life Technologies), Fc-CD40L (1 µg/ml, Enzo Life 
Sciences) and TNF (100 ng/ml, Adipogen).  
 
Chemotactism assay 
 DLBCL cells were incubated in bottom compartments of a 8-µM 24-transwell plate 
(Nunc) at 0.5 x 106 cells per ml. 72 h later, 0.2 x 106 purified neutrophils were added in upper 
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compartments. Rabbit anti CXCL-8 (Life Technologies) was used at 10 µg/ml. After 2 h 
incubation, neutrophils in bottom wells were stained with an anti-CD13 and CD16, and 
numerated by flow cytometry with an Accurri C6 set on a volume-based event acquisition.  
 
Epigenetic studies 
0.5 x 106 DLBCL cells per ml were incubated for 24 h with Trichostatin A (TSA, 500 
ng/ml, Sigma) or 72 h with Decitabine (10 µM, Sigma). DMSO was used as a vehicle control. 
Real time RT-PCR was performed as described above with forward and reverse primers for 
CXCL-8 5’-cggaaggaaccatctcactg-3’ and 5’-agcactccttggcaaaactg-3’, respectively. Expression 
levels were normalized using actin mRNA. Results were quantified using a standard curve 
generated with serial dilutions of input DNA. 
 
Statistics 
Data are presented as means ± s.d. Statistical analyses were performed with two-tailed 
unpaired Mann-Whitney U test on samples of equal size using the Prism software (Graphpad 
Software Inc., San Diego, CA, USA). P-values superior to 0.05 were considered as non-
significant. 
 
Results  
Blood neutrophils constitutively produce APRIL 
  Neutrophils usually produce their effector proteins at an immature stage and store these 
proteins in intracellular granules to release them upon activation at the inflammation site (30).  
Transcription of neutrophil effector proteins is commonly stopped at neutrophil maturity. We 
previously reported that APRIL production is also switched on early in immature neutrophils, but 
APRIL transcription drops by two third but does not stop in mature neutrophils, at least for 
mature neutrophils present in bone marrow (BM) (31). In the blood circulation, APRIL 
transcription in neutrophils did not stop as well, and was equal to that in mature neutrophils from 
BM (figure 1A, left panel). All blood neutrophils were reactive with Stalk-1, an antibody against 
APRIL identifying APRIL-producing cells (figure 1A, middle panel). We further observed 
constitutive APRIL secretion in 24h culture supernatants of neutrophils purified by sedimentation 
and FACS sorting according to morphology (figure 1A, right panel). The common activators 
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PMA, TNF and fMLP rapidly induced H2O2 release, a marker of neutrophil activation, from 
blood mature neutrophils (figure 1B, top left panel). However, only PMA and to a lesser extent 
TNF upregulated APRIL transcription (figure 1B, top right panel). Upregulation of APRIL 
transcription correlated with a concomitant increased accumulation of secreted APRIL in the 
supernatant (figure 1B, bottom panel). This argued against APRIL storage in neutrophils. Taken 
together, these results showed that APRIL secretion in neutrophils is constitutive and further 
upregulated by inflammatory stimuli. 
 
DLBCL tumor cells variably express the chemokine CXCL-8  
  The mechanism by which APRIL production varies in DLBCL lesions is presently 
unknown. Our previous work indicated that infiltrating neutrophils are a cellular source of 
APRIL in DLBCL lesions (24). Among APRILhigh DLBCL cases, we are now reporting a 
significant infiltration (mean = 25 per mm2, range 4-318) of neutrophils in about 75% of these 
cases (n=101). The demonstration that blood neutrophils constitutively produced APRIL 
indicates that variation of APRIL expression may originate from a differential neutrophil 
recruitment in tumor lesions. We selected representative APRILneg and APRILhigh patients, with 
the latter being infiltrated by elastase+ neutrophil producing APRIL (figure 2a, upper and middle 
panels). We profiled chemokine expression in lysates of frozen biopsies from these two patients. 
CXCL-8 was upregulated in the APRILhigh neutrophilhigh patient (figure 2A, bottom left panel). 
CXCL-8 is one ligand of CXCR-2 known as the main driver of neutrophil migration (32), but 
other chemokines may act on neutrophils (33). The neutrophil-specific chemokines CXCL-1, -12 
and CCL-2, -3, -4, -5 were not upregulated on the blot, and the remaining neutrophil-specific 
chemokines CXCL-2, -3, -5, -6 and CCL-7, -13, -14 were not detectable at the mRNA level in 
this patient (figure 1 sup). An ELISA confirmed the upregulation of CXCL-8 in lysates of 3 non-
necrotic DLBCL biopsies from APRILhigh patients (figure 2B). In situ staining with an anti-
CXCL-8 showed intracellular staining in cells harboring large central single nucleolus, 
reminiscent of immunoblastic DLBCL tumor cells (figure 2C). Costaining experiments 
confirmed that CXCL-8 was indeed present in the cytoplasm of CD20+ DLBCL tumor cells in 
lesions infiltrated by neutrophils but not in non-infiltrated lesions (figure 2D). We confirmed 
specific CXCL-8 expression by tumor cells at the mRNA level in CD20+ fraction of primary 
DLBCL but not in CD20- cells (Figure 2E). In this experiment, we did not detect CXCL-8 
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mRNA in CD20+ DLBCL tumor cells from non-infiltrated lesions. In these samples, Finally, 
CXCL-8 secretion was detected in the supernatant of CD20+ fraction of primary DLBCL from 
APRILhigh patients cultured for 3 days (mean = 175 pg/ml, range 30.42 – 445.27 pg/ml, n=3). In 
total, we observed CXCL-8 immunostaining in 95% of the case infiltrated by neutrophils. CXCL-
8 protein expression was undetectable in 90% of the APRILneg patients. These neutrophils 
infiltrated the tumor nest, in close vicinity with tumor cells (figure 2 sup). Tumoral necrotic cells 
were found in 30% of cases infiltrated by neutrophils (figure 3A sup). CXCL-8 production by 
neutrophils was found in 12% of infiltrated cases and was always associated with necrosis (figure 
3B sup). However, CXCL-8 production by neutrophils was never observed in non-necrotic cases. 
Finally, we also detected CXCL-8 in the supernatant of 11 of 24 DLBCL cell lines (figure 2F). In 
these 11 cell lines, CXCL-8 secretion was constitutive, and was not related to the cell of origin, 
since detected in the supernatant of both ABC-like (n=4) and GC-like (n=7) DLBCL subtypes. 
TNF and anti-BCR/CD40L never induced CXCL-8 secretion in DLBCL cell lines, but anti-
BCR/CD40L upregulated CXCL-8 secretion in 7 of the 11 CXCL-8+ cell lines. Taken together, 
our data show that some DLBCL tumor cells constitutively produce CXCL-8. A cognate T/B 
collaboration pathway, mimicked by anti-BCR/CD40L stimulation, may further upregulate this 
production.  
 
CXCL-8 recruits APRIL-producing neutrophils in DLBCL lesions  
In vitro CXCL-8+ DLBCL cell lines attracted significantly more neutrophils in a standard 
Boyden chamber assay than CXCL-8- DLBCL cell lines (figure 3A). Antibody-mediated 
inhibition showed the CXCL-8 dependent chemotactic activity of OCI-Ly18, the DLBCL cell 
line producing the most of CXCL-8 (see figure 2E), and the most efficient to in vitro recruit 
neutrophils (figure 3B). Expression of the two CXCL-8 receptors, CXCR-1 and -2, on the surface 
of blood mature neutrophils explained their chemotactic response to CXCL-8+ DLBCL cell lines 
(figure 3C). CXCL-8 has no murine ortholog, and human CXCL-8 does not efficiently cross-
react on mouse neutrophils (34). To demonstrate an in vivo chemotactic activity, we used 
humanized NOG immunodeficient mice. CD45intCD16+CD13+ mature neutrophils of human 
origin produced APRIL in BM of these mice (figure 4A). We further observed the presence of 
APRIL-producing cells harboring a nuclear morphology reminiscent of neutrophils, selectively 
infiltrating the CXCL-8+ OCI-Ly18 tumor xenografts made in these mice (figure 4B). These 
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APRIL-producing infiltrating cells were indeed neutrophils expressing elastase (figure 4C). This 
xenogeneic model reproduced the situation in patients in terms of expression pattern with all cells 
producing APRIL, and in terms of infiltration level with a mean of 55 cells per mm2, range 33-
143, n=3. Taken together, our data show that CXCL-8, produced by DLBCL tumor cells, 
efficiently recruits blood neutrophils. 
 
CXCL-8 production in DLBCL is a post-transformation event 
Among the 11 CXCL-8+ DLBCL cell lines, bcl-2 expression was detected in 7 of them. 
All the cell lines expressed the B-cell marker CD19, except one. All of them expressed HLA-DR. 
All cell lines differentially expressed CD27 and CD38, and 4 cell lines had undergone a switch 
IgG+/IgM- surface phenotype (figure 5a). Taken together, this revealed a wide heterogeneity in 
CXCL-8+ DLBCL. We neither observed CXCL-8 protein expression by immunohistochemistry 
in healthy GC B cells from tonsil nor CXCL-8 mRNA expression in CD19+ IgD+ CD38- naive, 
CD19+ CD38+ GC and CD19+ IgD- CD38- memory B cells (figure 5B, figure 4 sup). This shows 
that CXCL-8 induction in DLBCL is a post-tranformation event. In DLBCL patients, as in cell 
lines, CXCL-8 expression was not dependent on the cell of origin, since we detected APRILhigh 
neutrophilhigh phenotype in GC (n=31) and in non-GC subtypes (n=37). To gain insight into the 
pathway regulating CXCL-8 expression in DLBCL tumor cells, we performed DNA methylation 
inhibition with decitabine and upregulation of histone acetylation by histone deacetylase 
inhibition with trichostatin A (TSA) on a panel of 6 DLBCL cell lines CXCL-8+ and 6 DLBCL 
cell lines CXCL-8-. We applied decitabine and TSA for 3 days and 1 day, respectively. The 
higher toxicity of TSA on DLBCL cell lines explained the shortened incubation period with this 
reagent. Decitabine modulated positively CXCL-8 transcription in all DLBCL cell lines tested, 
with either an upregulation in CXCL-8+ cell lines, or induction of a detectable transcription in the 
other cell lines (figure 6A). TSA behaved very similarly with either upregulation or induction of 
CXCL-8 transcription. At the protein level, decitabine treatment increased CXCL-8 secretion in 
all the CXCL-8+ cell lines, and resulted in the faint detection of CXCL-8 in the supernatant of 
two CXCL-8- cell lines (figure 6B). We did not detect an increase in CXCL-8 protein level in cell 
supernatant after TSA treatment. This may be either due to the shorter time treatment or the 
sensitivity of CXCL-8 transport to histone deacetylases, as described for other proteins (35). 
Taken together, these experiments showed that the CXCL-8- DLBCL cell lines tested here still 
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contain a functional CXCL-8 locus, and this locus is kept silent by DNA methylation and histone 
hypoacetylation.  
 
 
Discussion 
In the present study, we observed a constitutive production of APRIL by blood circulating 
neutrophils. These cells do not store APRIL in exocytosis granules but rather constantly secrete 
it, resulting in a detectable accumulation of APRIL in neutrophil cell culture supernatants. Such 
secretion pattern by blood neutrophils may explain the steady state concentration in the ng/ml 
range reported for this cytokine in blood from healthy donors (36-38). Here, we show that blood 
neutrophils quite frequently infiltrate DLBCL, providing APRIL in DLBCL lesions. Such 
neutrophil infiltration is due to the constitutive production of CXCL-8 by tumor cells. We did not 
obtain evidences for the involvement of another chemokine involved. CXCL-8-producing 
DLBCLs are phenotypically heterogeneous, being either of the GC or the non-GC subtypes. By 
contrast, healthy GC B cells did not express CXCL-8. Rather, we show that epigenetic events 
leading to DNA demethylation and/or histone hyperacetylation induce CXCL-8 production by 
DLBCL. It is known that DLBCL are highly perturbated in their epigenome (39). These 
perturbations are variable among patients (40). Our present study indicates that epigenetic 
variations concern CXCL-8. The CXCL-8 gene is derepressable by DNA demethylation and 
histone hyperacetylation (41). The activation-induced cytidine deaminase (AID) strictly 
expressed in B cells from GC to mediate somatic hypermutations and class switching also 
induces DNA demethylation that derepress many genes in GC B cells (42). Derepression of 
CXCL-8 by DNA demethylation may either occur at that stage or in a post transformation event, 
considering the fact that AID remains active in DLBCL (43). Variation in histone acetylation is 
also a hallmark of DLBCL (44). Indeed, DLBCL frequently harbors inactivating mutations in the 
histone acetyl transferases CREB-binding protein (CREBBP) and p300 (45, 46). Thus, CXCL-8+ 
DLBCLs may represent tumor cells with a still active acetyl transferase activity. Taken together, 
these processes explain the variable presence of the tumor-promoting APRIL in DLBCL lesions. 
It is further interesting to note that CXCL-8 production may be amplified in situ. Indeed, an anti-
BCR/CD40L stimulus, which can be considered as an in vitro mimick of a cognate T-helper/B 
cell interaction increases CXCL-8 production by tumor cells. This latter effect is likely due to an 
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increase in AID and CREBBP/p300 expression by CD40 signaling (47, 48). To our knowledge, a 
BCR signalling did not result in the upregulation of these enzymes. CD40 signaling in DLBCL 
may occur in situ own to the frequent infiltration of T-helper cells in tumor lesions (49, 50). 
Levels of APRIL expression may even be further amplified in situ by TNF, a cytokine present in 
DLBCL lesions (51), and shown here to upregulate APRIL production by neutrophils. 
CXCL-8 production by tumor cells including colon, ovarian, prostate and bladder cancers 
has already been reported (52-55). It is believed that CXCL-8 promotes tumor development, 
when tumors aberrantly express CXCL-8 receptors, resulting in an autocrine stimulation loop 
(56). The CXCL-8 tumor-promoting pathway we are demonstrating here is different. Indeed, in 
DLBCL, CXCL-8 exerts a paracrine loop. Our present results are consistent with a recent report 
showing that a direct contact between tumor cells and neutrophils enhances in a BAFF/APRIL 
dependent manner the in vitro survival of DLBCL cell lines and primary cultures (57). Regarding 
CXCL-8 expression in DLBCL, mRNA and tissue protein reactivities have already been 
reported, but the cellular source was not identified (58). Consistent with our study is the report 
that high CXCL-8 concentration is associated to an impaired response to chemotherapy (59). 
Taken together, tumor-derived CXCL-8 promotes neutrophil infiltration, thereby providing a 
source of the DLBCL-promoting factor APRIL. Such neutrophil infiltration may thus accelerate 
DLBCL development.  
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LEGEND TO FIGURES 
Figure 1: blood neutrophils constitutively produce APRIL 
A) qRT-PCR analysis for APRIL mRNA in FACS-sorted mature BM and blood neutrophils. A 
value of one was arbitrarily given to mature BM neutrophils (left panel). Data are representative 
of three healthy donors. PBLs from healthy donors were surface-stained for CD13 and CD16, and 
for APRIL-production after cell permeabilization (middle panel). Overlaid histogram plots for 
gated CD13+CD16+ neutrophils are shown. Grey and black lines correspond to control Ig and 
Stalk-1 staining, respectively. Data are representative of at least twenty healthy donors. ELISA 
for APRIL in the supernatant of 24hr culture from unstimulated neutrophils (right panel). Data 
are representative of three donors. B) H2O2 production in unstimulated (NS) and stimulated 
neutrophils with PMA, TNF and fMLP (top left panel). Data show maximum relative light units 
(RLU) observed during a period of 10 min. APRIL mRNA expression level at 6 and 12 h was 
analysed by qRT-PCR (top right panel). Data were normalized using actin mRNA expression and 
are presented as fold increases compared to unstimulated conditions. Secreted APRIL was 
analysed by ELISA in culture supernatants at the indicated time points (bottom panel). Fold 
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increases compared to unstimulated conditions are shown. Data are representative of three 
healthy donors. *P<0.05. 
 
Figure 2: DLBCL tumor cells constitutively produce CXCL-8 
A) DLBCL biopsies were selected according to the level of APRIL expression (Stalk-1 staining, 
upper panel). APRIL-producing (Stalk-1 staining, green) neutrophils were identified by Elastase 
staining (red) (middle panel). The merge picture also shows Hoechst nuclear staining (blue). 
Scale bar = 10µm. Lysates of APRILneg and APRILhigh DLBCL biopsies were profiled for 
chemokine expression (bottom left panel). Dots corresponding to CXCL-8 are arrowed. Dots 
corresponding to other neutrophil-acting chemokines present on the blot are also indicated. B) 
CXCL-8 protein was quantified in lysates of the indicated DLBCL biopsies by ELISA. C) In situ 
CXCL-8 staining of the indicated biopsies. Figure is representative of a total of 101 patients. 
Scale bar = 20 µm. D) In situ fluorescence costaining of the indicated DLBCL biopsies for CD20 
(green) and CXCL-8 (red). Hoechst nuclear staining is also shown (blue). Figure is representative 
of three patients for each case. Scale bar = 20 µm. E) CXCL-8 mRNA expression in CD20+ and 
CD20- fraction of primary DLBCL cells. F) CXCL-8 concentration in the supernatant of 
unstimulated, anti-BCR/CD40L, and TNF-stimulated DLBCL cells lines. Figure is representative 
of at least five experiments. *P<0.05. 
 
Figure 3: in vitro chemotactic activity of CXCL-8+ DLBCL tumor cells for neutrophils 
A) Chemoattraction of purified human blood neutrophils by DLBCL cell lines. B) 
Chemoattraction by the DLBCL cell line OCI-Ly18 in the presence of an anti-CXCL-8 or control 
antibody (cIg). The figure is representative of three experiments. The fold increase compared to 
medium alone is shown. C) Surface expression of the indicated chemokine receptors on 
CD13+CD16+ gated blood neutrophils from healthy donors. Grey lines correspond to control Ig 
staining. Results are representative of at least three healthy donors. 
 
Figure 4: in vivo chemotactic activity of CXCL-8+ DLBCL tumor cells for neutrophils 
A) Bone marrow cells from humanized NOG mice were surface stained for human CD13, CD16 
and CD45, and for APRIL-production after cell permeabilization. Grey and black lines 
correspond to control Ig and Stalk-1 staining, respectively. B) Biopsies of the indicated DLBCL 
 18 
cell lines xenografted in NOG mice were stained for neutrophils (Elastase) and APRIL-producing 
cells (Stalk-1). Scale bar = 50 µm. C) Fluorescence costaining of a OCI-Ly18 biopsy for APRIL-
producing cells (Stalk-1, red) and neutrophils (Elastase, green). The merge picture also shows 
Hoechst nuclear staining (blue). Scale bar = 20 µm. Results are representative of at least three 
different mice. 
 
Figure 5: Heterogeneous phenotypes for CXCL-8+ DLBCL tumor cells 
A) CXCL-8+ DLBCL cell lines were analysed by flow cytometry for the indicated surface 
markers. Bcl-2 expression was analysed after cell permeabilization. Histogram plots are shown. 
B) CXCL-8 mRNA expression in the control OCI-Ly18 DLBCL cell line and purified naïve, GC 
and memory B cells from tonsils. Figure is representative of three tonsillitis patients 
 
Figure 6: epigenetic regulation of CXCL-8 expression in DLBCL 
A) qRT-PCR analysis for CXCL-8 mRNA in DLBCL cell lines treated with TSA, decitabine or 
DMSO vehicle control. Data are representative of three experiments, *P<0.05 vs DMSO-treated 
group. B) CXCL-8 concentration in the supernatant of cell lines treated with TSA, Decitabine or 
DMSO vehicle control. *P<0.05 vs DMSO treated 
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CXCL-8- CXCL-8+ 
CXCL-8- CXCL-8+ 
Figure 1 sup 
CXCL-8 is the unique neutrophil chemokine detectable in DLBCL biopsies 
RT-PCR analysis for the indicated neutrophil-specific chemokines. Positive control for 
CXCL-2, -6, -7, CCL-7 and CXCL-3, -5, CCL-13, -14 was total PBL and tonsil mRNA, 
respectively. 
Figure 2 sup 
CD20 APRIL merge 
APRIL-producing neutrophils infiltrate the tumor nest 
Costaining for CD20 (red) and APRIL-producing cells (Stalk-1, green). Scale bar = 20 μm. 
Figure 3 sup 
CXCL-8+ neutrophils are present in DLBCL necrotic tumors 
A) APRIL immunostaining of neutrophils from a DLBCL biopsy with necrosis. Necrotic cells with pycnotic nuclei 
are arrowed . Figure is representative of 30 cases. B) CXCL-8 immunostaining of a DLBCL biopsy associated 
with necrosis. CXCL-8+ neutrophils with polymorph nuclei are arrowed. Figure is representative of 12 cases. 
Scale bar = 20 μm. 
A B 
Figure 4 sup 
Healthy B-cells are CXCL-8 negative 
In situ CXCL-8 staining of a human tonsil GC. Figure is representative of five tonsillitis patients. 
Scale bar = 100 µm.  
